AbbVie Positive Topline Results from Phase 2 for Ovarian Cancer

 

• PICCOLO trial met its primary endpoint of objective response rate (ORR)
• Data from the study will be presented at a future medical meeting

AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE^®) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%).

In addition, the median duration of response (DOR), a key secondary endpoint, was 8.25 months.

The safety profile of mirvetuximab soravtansine was consistent with findings from previous studies, and no new safety concerns were identified. Full data from the PICCOLO study will be presented at a future medical meeting.

https://www.biospace.com/article/releases/abbvie-announces-positive-topline-results-from-phase-2-piccolo-trial-evaluating-mirvetuximab-soravtansine-elahere-for-high-folate-receptor-alpha-fr%ce%b1-expressing-platinum-sensitive-ovarian-cancer/